Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme reductase, can significantly reduce the incidence of atherosclerotic cardiovascular disease (ASCVD) events. Recently, some guidelines and consensus have suggested that the patients with acute coronary syndromes (ACS) should start high-intensity statin therapy early after admission. But, Chinese patients tend to have higher incidence of side effects in statins treatment than Caucasians. Therefore, particular attention should be paid to the adverse reactions in Chinese population after high-intensity statin treatment. In this article, we reviewed the safety of high-intensity statin therapy in ACS patients in China, and provides a reference for clinical practice.